Dyno
Dyno Therapeutics is a genetic technologies company applying AI to solve the grand challenge of in vivo gene delivery.
Challenge
How do you position a company at the intersection of frontier AI and gene delivery as the partner of choice for the world’s leading therapeutic developers, all while establishing an entirely new framework for the future of patient-driven therapeutic development?
Approach
Thermal partnered with Dyno to build the communications strategy behind the company’s most consequential growth phase.
-
- Shaped Dyno’s identity as an AI-driven innovator: Built a messaging foundation to consistently differentiate Dyno’s platform model from legacy gene therapy approaches across media, conferences, and partner-facing communications.
- Executed high-stakes partnership announcements: Coordinated Dyno’s announcement of a strategic collaboration with Roche potentially worth over $1 billion and technical partnership with NVIDIA to advance biological sequence design. Supported continuing milestone coverage as Roche exercised its option on Dyno’s next-generation AAV vector for neurological gene therapy and Astellas exercised its option for muscle gene therapy.
- Built the Genetic Agency Technology Conference (GATC): Played an active role in organizing Dyno’s inaugural GATC, a first-of-its-kind event of 200 patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers around the goal of genetic agency. Managed the press and social strategy, securing trade coverage and speaker engagement.
- Drove sustained scientific, technical, and ecosystem milestone coverage: Managed PR activities across Dyno’s busy launch cadence, including three best-in-class capsids presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, a muscle-targeting capsid presented at GATC, and the launch of Dyno’s agentic AI suite at NVIDIA GTC 2026. Coordinated media for Frontiers Network ecosystem launch and expansion for innovative gene therapy developers.
- Assisted with original video and social content. Created a sustained stream of video and social programming around GATC and patient stories, extending audience reach and reinforcing Dyno’s voice as a defining authority in AI, gene delivery, and patient-driven therapeutic development.
Impact
Through our partnership, Dyno has:
-
- Secured coverage across business and trade media: Dyno’s partnerships and launches generated placements in Bloomberg, VentureBeat, Quartz, Endpoints News, Fierce Biotech, STAT News, Genetic Engineering & Biotechnology News (GEN), and the Boston Business Journal.
- Established genetic agency as a recognized category concept: Dyno’s “genetic agency” framing took hold across earned media, conference coverage, and executive communications, giving reporters, investors, and partners a consistent lens for Dyno’s mission.
- Launched GATC as an industry forum: The inaugural conference trade coverage and established GATC as a recurring convening point for the gene delivery ecosystem. Continuing video and social content kept the conversation alive after GATC, turning an annual one-day event into an ongoing presence in the feeds of therapeutic developers, investors, and patient advocates.
“Our approach combines extensive in vivo data with the world’s most advanced AI models for sequence-function prediction, empowering Dyno capsid engineers with industry-leading capabilities for solving the longstanding challenge of therapeutic gene delivery. Dyno’s platform brings the entire field closer to realizing a future where all gene therapies are safe, effective, and widely accessible to all patients who need them.”
Eric Kelsic – CEO of Dyno Therapeutics
$1+BN
Roche partnership announced
150M
Total readership
200

